A Review of Macrophage Migration Inhibitory Factor in Tumourigenesis
Keywords:
MIF, Tumourigenesis, Macrophage Migration Inhibitory FactorAbstract
With its unique tautomerase activity, macrophage migration inhibitory factor (MIF) is a multi-functional pro-inflammatory cytokine implicated in the pathogenesis of numerous types of cancer. Through a variety of mechanisms MIF is tumourigenic, pro-inflammatory and pro-angiogenic. As a result of its central role in both cancer and inflammation many MIF inhibitors are currently in development, with recent studies yielding impressive results.
References
Agarwal, R. et al., 2007. Macrophage migration inhibitory factor expression in ovarian cancer. American Journal of Obstetrics and Gynecology, 196(4), pp. 348.e1-348.e5.
Amin, M. et al., 2003. Migration Inhibitory Factor Mediates Angiogenesis via Mitogen-Activated Protein Kinase and Phosphatidylinositol Kinase. Circulation Research, Volume 93, pp. 321-329.
Apte, R. et al., 1998. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege.. Journal of Immunology, 160(12), pp. 5693-5696.
Arisawa, T. et al., 2008. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncology Reports, 19(1), pp. 223-228.
Bacher, M. et al., 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.. Proceedings of the National Academy of Sciences U.S.A, 93(15), pp. 7849-7854.
Bai, F. et al., 2012. A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF). Journal of Biological Chemistry , 287(36), pp. 30653-30663.
Baugh, J. et al., 2002. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes and Immunity, 3(3), pp. 170-176.
Baugh, J. et al., 2006. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochemical and Biophysical Research Communications, 347(4), pp. 895-903.
Bloom, B. & Bennett, B., 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153(3731), pp. 80-82.
Bucala, R., 2000. Signal Transduction: a most interesting factor. Nature, 408(6809), pp. 146-147.
Butrym, A. et al., 2013. High CD74 expression coreelates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. Medicinal Oncology, 30(2), p. 560.
Calandra, T., Bernhagen, J., Mitchell, R. & Bucala, R., 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.. Journal of Experimental Medicine, 179(6), pp. 1895-1902.
Chesney, J. et al., 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.. Molecular Medicine, 5(3), pp. 181-191.
Choi, S. et al., 2012. Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. Journal of Immunology, 189(8), pp. 3905-3913.
Conroy, H., Mawhinney, L. & Donnelly, S., 2010. In!ammation and cancer: macrophage migration inhibitory factor (MIF): the potential missing link. Quarterly Journal of Medicine, Issue 103, pp. 831-836.
David, J., 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substance formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences, 56(1), pp. 72-77.
De Souza, M., Curioni, O., Kanda, J. & De Carvalho, M., 2014. Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cel carcinoma. Oncology Letters, 8(5), pp. 2267-2275.
Dong, L. et al., 2009. A gene expression ratio-based diagnostic test for bladder cancer. Advances and Applications in Bioinformatics and Chemistry, Volume 2, pp. 17-22.
Donnelly, S. et al., 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine, 3(3), pp. 320-323.
Donn, R. et al., 2001. A novel 5’-!anking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis.. Arthritis & Rheumatology, 44(8), pp. 1782-1785.
Fingerle-Rowson, G. et al., 2009. A tautomerase-null macrophage migration inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Molecular Cell Biology, 29(7), pp. 1922-1932.
Fingerle-Rowson, G. et al., 2009. A Tautomerase-Null Macrophage Migration- Inhibitory Factor (MIF) Gene Knock-In Mouse Model Reveals That Protein Interactions and Not Enzymatic Activity Mediate MIF-Dependent Growth Regulation. Molecular Cell Biology, 29(7), pp. 1922-1932.
Fu, H. et al., 2010. Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vascular smooth muscle cells via HIF-1alpha dependent pathway.. BMC Cell Biology, Volume 11, p. 66.
Gabrilovich, D. & Nagaraj, S., 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, Volume 9, pp. 162-174.
Graham, A., Falcone, T. & Nothnick, W., 2015. The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival. Human Reproduction, 30(3), pp. 642- 652.
Harris, A., 2002. Hypoxia — a key regulatory factor in tumour growth. Nature Reviews Cancer, Volume 2, pp. 38-47.
Heck, J. et al., 2008. The epidemiology of neuroblastoma: a review. Paediatric and
Perinatal Epidemiology, 23(2), pp. 125-143.
He, L. et al., 2015. Macrophage migration inhibitory factor as a potential
prognostic factor in gastric cancer.. World Journal of Gastroenterology,
21(34), pp. 9916-9926.
He, X. et al., 2009. Macrophage Migration Inhibitory Factor Promotes Colorectal
Cancer. Molecular Medicine, 15(1-2), pp. 1-10.
Hudson, J. et al., 1999. A Proin!ammatory Cytokine Inhibits P53 Tumor
Suppressor Activity. The Journal of Experimental Medicine, 190(10), pp. 1375-
1382.
Ioannou, K. et al., 2014. ISO-66, a novel inhibitor of macrophage migration
inhibitory. International Journal of Oncology, 45(4), pp. 1457-1468. Jung, H., Seong, H. & Ha, H., 2008. Critical Role of Cysteine Residue 81 of
Macrophage Migration Inhibitory Factor (MIF) in MIF-induced Inhibition of
p53 Activity. Journal of Biological Chemistry, 283(29), pp. 20383-20396. Koong, A. et al., 2000. Candidate genes for the hypoxic tumor phenotype. Cancer
Research, 60(4), pp. 883-887.
Lane, D., 1992. p53, Guardian of the Genome. Nature, Volume 358, pp. 15-16.
Leng, L. et al., 2003. MIF signal transduction initiated by binding to CD74.. Journal
of Experimental Medicine, 197(11), pp. 1467-1476.
Liu, N. et al., 2013. MiR-451 inhibits cell growth and invasion by targeting MIF and
is associated with survival in nasopharyngeal carcinoma. Molecular Cancer,
Volume 12, p. 123.
Lubetsky, J. et al., 1999. Pro-1 of macrophage migration inhibitory factor
functions as a catalytic base in the phenylpyruvate tautomerase activity..
Biochemistry, 38(22), pp. 7346-7354.
Lue, H. et al., 2007. Macrophage migration inhibitory factor (MIF) promotes
cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the
control of autocrine MIF activity.. Oncogene, 26(35), pp. 5046-5059. Mawhinney, L. et al., 2015. Macrophage Migration Inhibitory Factor (MIF)
Enzymatic Activity and Lung Cancer. Molecular Medicine, Volume 20, pp.
729-735.
Mazzoni, A. et al., 2002. Myeloid suppressor lines inhibit T cell responses by an
NO-dependent mechanism. Journal of Immunology, 168(2), pp. 689-695. Meyer-Siegler, K., Bellino, M. & Tannenbaum, M., 2002. Macrophage migration inhibitory factor evaluation compared with prostate speci#c antigen as a
biomarker in patients with prostate carcinoma. Cancer, 94(5), pp. 1449-1456. Meyer-Siegler, K. et al., 2006. Inhibition of Macrophage Migration Inhibitory
Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145
Prostate Cancer Cells. Journal of Immunology, 177(12), pp. 8730-8739. Meyer-Siegler, K., Iszkowski, K. & Vera, P., 2005. Further evidence for increased
macrophage migration inhibitory factor expression in prostate cancer. BMC
Cancer, Volume 5, p. 73.
Meyer-Siegler, K. et al., 2007. Macrophage migration inhibitory factor (MIF) gene
polymorphisms are associated with increased prostate cancer incidence.
Genes and Immunity, 8(8), pp. 646-652.
Mitchell, R. et al., 2002. Macrophage migration inhibitory factor (MIF) sustains
macrophage proin!ammatory function by inhibiting p53: regulatory role in the innate immune response.. Proceedings of the National Academy of Sciences U.S.A, 99(1), pp. 345-350.
Mitchell, R., Metz, C., Peng, T. & Bucala, R., 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action.. Journal of Biological Chemistrt, 274(25), pp. 18100-18106.
Mittelbronn, M. et al., 2011. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 122(3), pp. 353-365.
Morand, E., M, L. & J, B., 2006. A new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Review Drug Discovery, 5(5), pp. 399-410.
Muramaki, M., Miyake, H., Yamada, Y. & Hara, I., 2006. Clinical Utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncology Reports, 15(1), pp. 253-257.
Nguyen, M. et al., 2003. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions.. Journal of Biological Chemistry, 287(36), pp. 33654- 33671.
No, Y., Lee, S., Kumar, A. & Yun, C., 2015. HIF1α-Induced by Lysophosphatidic Acid Is Stabilized via Interaction with MIF and CSN5.. PLoS One, 10(9), p. e0137513.
Oda, S. et al., 2008. Macrophage Migration Inhibitory Factor Activates Hypoxia- Inducible Factor in a p53-Dependent Manner. PLoS One, 3(5), p. e2215.
Ogawa, H. et al., 2000. An Antibody For Macrophage Migration Inhibitory Factor Supresses Tumour Growth And Inhibits Tumour-Associated Angiogenesis. Cytokine, 12(4), pp. 309-314.
Oliveira, C. et al., 2014. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer.
Otterstrom, C. et al., 2014. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. British Journal of Cancer, 110(8), pp. 2040-2046.
Petrenko, O. et al., 2003. Macrophage migration inhibitory factor de#ciency is associated with altered cell growth and reduced susceptibility to Ras- mediated transformation. Journal of Biological Chemistry, 278(13), pp. 11078-11085.
Petrenko, O. & Moll, U., 2005. Macrophage Migration Inhibitory Factor MIF Interferes with the Rb-E2F Pathway. Molecular Cell, 17(2), pp. 225-236.
Qiang, Z. et al., 2008. Expression of Macrophage Migration Inhibitory Factor (MIF) by Neuroblastoma Leads to the Inhibition of Anti-Tumor T Cell Reactivity In
Vivo. Journal of Immunology, 181(3), pp. 1877-1886.
Ren, Y. et al., 2005. Macrophage Migration Inhibitory Factor Stimulates. Annals of
Surgery, 242(1), pp. 55-63.
Repp, A., Mayhew, E., Apte, S. & Niederkorn, J., 2000. Human uveal melanoma cells
produce macrophage migration inhibitory factor to prevent lysis by NK cells.
Journal of Immunology, 165(2), pp. 710-715.
Rice, E. et al., 2003. Induction of MIF synthesis and secretion by tubular epithelial
cells: A novel action of angiotensin II. Kidney International, 63(4), pp. 1265-
1275.
Rossi, A. et al., 1998. Human circulating eosinophils secrete macrophage
migration inhibitory factor (MIF). Potential role in asthma.. Journal of
Clinical Investigation, 101(12), pp. 2869-2874.
Shimizu, T. et al., 2004. Macrophage migration inhibitory factor is induced by
thrombin and factor Xa in endothelial cells.. Journal of Biological Chemistry ,
279(14), pp. 13729-13737.
Shi, X. et al., 2006. CD44 is the signaling component of the macrophage
migration inhibitory factor-CD74 receptor complex.. Immunity, 25(4), pp.
595-606.
Simpson, K., Templeton, D. & Cross, J., 2012. Macrophage migration inhibitory
factor promotes tumour growth and metastasis by inducing myeloid-derived suppressor cells in the tumour micro-environment. Journal of Immunology, 189(12), pp. 533-5540.
Stahl, J. et al., 2004. Deregulated Akt3 activity promotes development of malignant melanoma.. Cancer Research, 64(19), pp. 7002-7010.
Strüßmann, T. et al., 2013. Platelets are a previously unrecognised source of MIF.. Thrombosis and Haemostasis, 110(5), pp. 1004-1013.
Subbannayya, T. et al., 2015. Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer. BMC Cancer, Volume 15, p. 843.
Swope, M., SUn, H., Blake, P. & Lolis, E., 1998. Direct link between cytokine activity and catalytic site for macrophage migration inhibitory factor. EMBO Journal, 17(13), pp. 3534-3541.
Takahashi, H. et al., 2013. Macrophage Migration Inhibitory Factor and Stearoyl- CoA Desaturase 1: Potential Prognostic Markers for Soft Tissue Sarcomas
Based on Bioinformatics Analyses. PLoS One, 8(10), p. e78250.
Tang, Y. et al., 2015. microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma. International
Journal of Clinical and Experimental Pathology, 8(12), pp. 15611-15621. Thiele, M. & Bernhagen, J., 2005. Link Between Macrophage Migration Inhibitory Factor and Cellular Redox Regulation. Antioxidants & Redox Signalling, 7(9-
10), pp. 1234-1248.
Vaupel, P., 2008. Hypoxia and aggressive tumor phenotype: implications for
therapy and prognosis.. Oncologist, 13(Supplement 3), pp. 21-26.
Winner, M. et al., 2007. Ampli#cation of tumor hypoxic responses by macrophage
migration inhibitory factor-dependent hypoxia-inducible factor
stabilization.. Cancer Research, 67(1), pp. 186-193.
Winner, M. et al., 2008. A novel, macrophage migration inhibitory factor suicide
substrate inhibits motility and growth of lung cancer cells. Cancer Research,
68(18), pp. 7253-7257.
Xiang, T. et al., 2015. The MIF -173G/C gene polymorphism increase
gastrointestinal cancer and hematological malignancy risk: evidence from a meta-analysis and FPRP test. International Journal of Clinical and Experimental Medicine, 8(9), pp. 15949-15957.
Xu, L. et al., 2014. Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays. Journal of Medicinal Chemistry, 57(9), pp. 3737-3745.
Xu, X. et al., 2008. Overexpression of macrophage migration inhibitory. Cancer letters, Volume 261, pp. 147-157.
Yan, X., Orentas, R. & Johnson, B., 2006. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.. Cytokine, 33(4), pp. 188-198.
Zhang, W. & Liu, H., 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research, 12(1), pp. 9-18.
Zhang, X. et al., 2015. The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis. OncoTargets and Therapy, 10(8), pp. 601-613.
Amin, M. et al., 2003. Migration Inhibitory Factor Mediates Angiogenesis via Mitogen-Activated Protein Kinase and Phosphatidylinositol Kinase. Circulation Research, Volume 93, pp. 321-329.
Apte, R. et al., 1998. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege.. Journal of Immunology, 160(12), pp. 5693-5696.
Arisawa, T. et al., 2008. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncology Reports, 19(1), pp. 223-228.
Bacher, M. et al., 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.. Proceedings of the National Academy of Sciences U.S.A, 93(15), pp. 7849-7854.
Bai, F. et al., 2012. A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF). Journal of Biological Chemistry , 287(36), pp. 30653-30663.
Baugh, J. et al., 2002. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes and Immunity, 3(3), pp. 170-176.
Baugh, J. et al., 2006. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochemical and Biophysical Research Communications, 347(4), pp. 895-903.
Bloom, B. & Bennett, B., 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153(3731), pp. 80-82.
Bucala, R., 2000. Signal Transduction: a most interesting factor. Nature, 408(6809), pp. 146-147.
Butrym, A. et al., 2013. High CD74 expression coreelates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. Medicinal Oncology, 30(2), p. 560.
Calandra, T., Bernhagen, J., Mitchell, R. & Bucala, R., 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.. Journal of Experimental Medicine, 179(6), pp. 1895-1902.
Chesney, J. et al., 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.. Molecular Medicine, 5(3), pp. 181-191.
Choi, S. et al., 2012. Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. Journal of Immunology, 189(8), pp. 3905-3913.
Conroy, H., Mawhinney, L. & Donnelly, S., 2010. In!ammation and cancer: macrophage migration inhibitory factor (MIF): the potential missing link. Quarterly Journal of Medicine, Issue 103, pp. 831-836.
David, J., 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substance formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences, 56(1), pp. 72-77.
De Souza, M., Curioni, O., Kanda, J. & De Carvalho, M., 2014. Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cel carcinoma. Oncology Letters, 8(5), pp. 2267-2275.
Dong, L. et al., 2009. A gene expression ratio-based diagnostic test for bladder cancer. Advances and Applications in Bioinformatics and Chemistry, Volume 2, pp. 17-22.
Donnelly, S. et al., 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine, 3(3), pp. 320-323.
Donn, R. et al., 2001. A novel 5’-!anking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis.. Arthritis & Rheumatology, 44(8), pp. 1782-1785.
Fingerle-Rowson, G. et al., 2009. A tautomerase-null macrophage migration inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Molecular Cell Biology, 29(7), pp. 1922-1932.
Fingerle-Rowson, G. et al., 2009. A Tautomerase-Null Macrophage Migration- Inhibitory Factor (MIF) Gene Knock-In Mouse Model Reveals That Protein Interactions and Not Enzymatic Activity Mediate MIF-Dependent Growth Regulation. Molecular Cell Biology, 29(7), pp. 1922-1932.
Fu, H. et al., 2010. Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vascular smooth muscle cells via HIF-1alpha dependent pathway.. BMC Cell Biology, Volume 11, p. 66.
Gabrilovich, D. & Nagaraj, S., 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, Volume 9, pp. 162-174.
Graham, A., Falcone, T. & Nothnick, W., 2015. The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival. Human Reproduction, 30(3), pp. 642- 652.
Harris, A., 2002. Hypoxia — a key regulatory factor in tumour growth. Nature Reviews Cancer, Volume 2, pp. 38-47.
Heck, J. et al., 2008. The epidemiology of neuroblastoma: a review. Paediatric and
Perinatal Epidemiology, 23(2), pp. 125-143.
He, L. et al., 2015. Macrophage migration inhibitory factor as a potential
prognostic factor in gastric cancer.. World Journal of Gastroenterology,
21(34), pp. 9916-9926.
He, X. et al., 2009. Macrophage Migration Inhibitory Factor Promotes Colorectal
Cancer. Molecular Medicine, 15(1-2), pp. 1-10.
Hudson, J. et al., 1999. A Proin!ammatory Cytokine Inhibits P53 Tumor
Suppressor Activity. The Journal of Experimental Medicine, 190(10), pp. 1375-
1382.
Ioannou, K. et al., 2014. ISO-66, a novel inhibitor of macrophage migration
inhibitory. International Journal of Oncology, 45(4), pp. 1457-1468. Jung, H., Seong, H. & Ha, H., 2008. Critical Role of Cysteine Residue 81 of
Macrophage Migration Inhibitory Factor (MIF) in MIF-induced Inhibition of
p53 Activity. Journal of Biological Chemistry, 283(29), pp. 20383-20396. Koong, A. et al., 2000. Candidate genes for the hypoxic tumor phenotype. Cancer
Research, 60(4), pp. 883-887.
Lane, D., 1992. p53, Guardian of the Genome. Nature, Volume 358, pp. 15-16.
Leng, L. et al., 2003. MIF signal transduction initiated by binding to CD74.. Journal
of Experimental Medicine, 197(11), pp. 1467-1476.
Liu, N. et al., 2013. MiR-451 inhibits cell growth and invasion by targeting MIF and
is associated with survival in nasopharyngeal carcinoma. Molecular Cancer,
Volume 12, p. 123.
Lubetsky, J. et al., 1999. Pro-1 of macrophage migration inhibitory factor
functions as a catalytic base in the phenylpyruvate tautomerase activity..
Biochemistry, 38(22), pp. 7346-7354.
Lue, H. et al., 2007. Macrophage migration inhibitory factor (MIF) promotes
cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the
control of autocrine MIF activity.. Oncogene, 26(35), pp. 5046-5059. Mawhinney, L. et al., 2015. Macrophage Migration Inhibitory Factor (MIF)
Enzymatic Activity and Lung Cancer. Molecular Medicine, Volume 20, pp.
729-735.
Mazzoni, A. et al., 2002. Myeloid suppressor lines inhibit T cell responses by an
NO-dependent mechanism. Journal of Immunology, 168(2), pp. 689-695. Meyer-Siegler, K., Bellino, M. & Tannenbaum, M., 2002. Macrophage migration inhibitory factor evaluation compared with prostate speci#c antigen as a
biomarker in patients with prostate carcinoma. Cancer, 94(5), pp. 1449-1456. Meyer-Siegler, K. et al., 2006. Inhibition of Macrophage Migration Inhibitory
Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145
Prostate Cancer Cells. Journal of Immunology, 177(12), pp. 8730-8739. Meyer-Siegler, K., Iszkowski, K. & Vera, P., 2005. Further evidence for increased
macrophage migration inhibitory factor expression in prostate cancer. BMC
Cancer, Volume 5, p. 73.
Meyer-Siegler, K. et al., 2007. Macrophage migration inhibitory factor (MIF) gene
polymorphisms are associated with increased prostate cancer incidence.
Genes and Immunity, 8(8), pp. 646-652.
Mitchell, R. et al., 2002. Macrophage migration inhibitory factor (MIF) sustains
macrophage proin!ammatory function by inhibiting p53: regulatory role in the innate immune response.. Proceedings of the National Academy of Sciences U.S.A, 99(1), pp. 345-350.
Mitchell, R., Metz, C., Peng, T. & Bucala, R., 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action.. Journal of Biological Chemistrt, 274(25), pp. 18100-18106.
Mittelbronn, M. et al., 2011. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 122(3), pp. 353-365.
Morand, E., M, L. & J, B., 2006. A new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Review Drug Discovery, 5(5), pp. 399-410.
Muramaki, M., Miyake, H., Yamada, Y. & Hara, I., 2006. Clinical Utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncology Reports, 15(1), pp. 253-257.
Nguyen, M. et al., 2003. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions.. Journal of Biological Chemistry, 287(36), pp. 33654- 33671.
No, Y., Lee, S., Kumar, A. & Yun, C., 2015. HIF1α-Induced by Lysophosphatidic Acid Is Stabilized via Interaction with MIF and CSN5.. PLoS One, 10(9), p. e0137513.
Oda, S. et al., 2008. Macrophage Migration Inhibitory Factor Activates Hypoxia- Inducible Factor in a p53-Dependent Manner. PLoS One, 3(5), p. e2215.
Ogawa, H. et al., 2000. An Antibody For Macrophage Migration Inhibitory Factor Supresses Tumour Growth And Inhibits Tumour-Associated Angiogenesis. Cytokine, 12(4), pp. 309-314.
Oliveira, C. et al., 2014. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer.
Otterstrom, C. et al., 2014. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. British Journal of Cancer, 110(8), pp. 2040-2046.
Petrenko, O. et al., 2003. Macrophage migration inhibitory factor de#ciency is associated with altered cell growth and reduced susceptibility to Ras- mediated transformation. Journal of Biological Chemistry, 278(13), pp. 11078-11085.
Petrenko, O. & Moll, U., 2005. Macrophage Migration Inhibitory Factor MIF Interferes with the Rb-E2F Pathway. Molecular Cell, 17(2), pp. 225-236.
Qiang, Z. et al., 2008. Expression of Macrophage Migration Inhibitory Factor (MIF) by Neuroblastoma Leads to the Inhibition of Anti-Tumor T Cell Reactivity In
Vivo. Journal of Immunology, 181(3), pp. 1877-1886.
Ren, Y. et al., 2005. Macrophage Migration Inhibitory Factor Stimulates. Annals of
Surgery, 242(1), pp. 55-63.
Repp, A., Mayhew, E., Apte, S. & Niederkorn, J., 2000. Human uveal melanoma cells
produce macrophage migration inhibitory factor to prevent lysis by NK cells.
Journal of Immunology, 165(2), pp. 710-715.
Rice, E. et al., 2003. Induction of MIF synthesis and secretion by tubular epithelial
cells: A novel action of angiotensin II. Kidney International, 63(4), pp. 1265-
1275.
Rossi, A. et al., 1998. Human circulating eosinophils secrete macrophage
migration inhibitory factor (MIF). Potential role in asthma.. Journal of
Clinical Investigation, 101(12), pp. 2869-2874.
Shimizu, T. et al., 2004. Macrophage migration inhibitory factor is induced by
thrombin and factor Xa in endothelial cells.. Journal of Biological Chemistry ,
279(14), pp. 13729-13737.
Shi, X. et al., 2006. CD44 is the signaling component of the macrophage
migration inhibitory factor-CD74 receptor complex.. Immunity, 25(4), pp.
595-606.
Simpson, K., Templeton, D. & Cross, J., 2012. Macrophage migration inhibitory
factor promotes tumour growth and metastasis by inducing myeloid-derived suppressor cells in the tumour micro-environment. Journal of Immunology, 189(12), pp. 533-5540.
Stahl, J. et al., 2004. Deregulated Akt3 activity promotes development of malignant melanoma.. Cancer Research, 64(19), pp. 7002-7010.
Strüßmann, T. et al., 2013. Platelets are a previously unrecognised source of MIF.. Thrombosis and Haemostasis, 110(5), pp. 1004-1013.
Subbannayya, T. et al., 2015. Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer. BMC Cancer, Volume 15, p. 843.
Swope, M., SUn, H., Blake, P. & Lolis, E., 1998. Direct link between cytokine activity and catalytic site for macrophage migration inhibitory factor. EMBO Journal, 17(13), pp. 3534-3541.
Takahashi, H. et al., 2013. Macrophage Migration Inhibitory Factor and Stearoyl- CoA Desaturase 1: Potential Prognostic Markers for Soft Tissue Sarcomas
Based on Bioinformatics Analyses. PLoS One, 8(10), p. e78250.
Tang, Y. et al., 2015. microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma. International
Journal of Clinical and Experimental Pathology, 8(12), pp. 15611-15621. Thiele, M. & Bernhagen, J., 2005. Link Between Macrophage Migration Inhibitory Factor and Cellular Redox Regulation. Antioxidants & Redox Signalling, 7(9-
10), pp. 1234-1248.
Vaupel, P., 2008. Hypoxia and aggressive tumor phenotype: implications for
therapy and prognosis.. Oncologist, 13(Supplement 3), pp. 21-26.
Winner, M. et al., 2007. Ampli#cation of tumor hypoxic responses by macrophage
migration inhibitory factor-dependent hypoxia-inducible factor
stabilization.. Cancer Research, 67(1), pp. 186-193.
Winner, M. et al., 2008. A novel, macrophage migration inhibitory factor suicide
substrate inhibits motility and growth of lung cancer cells. Cancer Research,
68(18), pp. 7253-7257.
Xiang, T. et al., 2015. The MIF -173G/C gene polymorphism increase
gastrointestinal cancer and hematological malignancy risk: evidence from a meta-analysis and FPRP test. International Journal of Clinical and Experimental Medicine, 8(9), pp. 15949-15957.
Xu, L. et al., 2014. Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays. Journal of Medicinal Chemistry, 57(9), pp. 3737-3745.
Xu, X. et al., 2008. Overexpression of macrophage migration inhibitory. Cancer letters, Volume 261, pp. 147-157.
Yan, X., Orentas, R. & Johnson, B., 2006. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.. Cytokine, 33(4), pp. 188-198.
Zhang, W. & Liu, H., 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research, 12(1), pp. 9-18.
Zhang, X. et al., 2015. The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis. OncoTargets and Therapy, 10(8), pp. 601-613.
Downloads
Published
2016-01-01
How to Cite
Hartnett, J. (2016). A Review of Macrophage Migration Inhibitory Factor in Tumourigenesis. Trinity Student Medical Journal . Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1959
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
